16 Mar / 22
VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Absci Lead AI Scientist Joshua Meier will be presenting
17 Feb / 22
VANCOUVER, Wash., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the following
07 Jan / 22
Collaboration to leverage Absci’s Deep Learning-Enabled Drug Creation™ and Bionic Protein™ technologies VANCOUVER, Wash., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the
05 Jan / 22
VANCOUVER, Wash., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming
Displaying 21 - 26 of 26